Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Nassif ME, et al
The FDA initially approved subcutaneous (SC) use Exenatide in 2005 and an oral version of semaglutide in 2019.2,3 Initially, GLP-1s were used exclusively for individuals with type 2 diabetes (T2DM) as a means to better control their blood sugar when paired with diet and exercise.2 Now their use is growing exponentially due to their success in helping patients achieve significant weight loss
Both are dominated by mostly mild-to-moderate gastrointestinal effects, but the labeling differs
Device-specific vigilance guidance: in vitro diagnostic (IVD) blood glucose monitors point of care testing and home use
US$ 23.43
US$ 27.98
US$ 20.22
US$ 22.50
